Jefferies analyst Michael Yee maintains $Biogen (BIIB.US)$ with a buy rating, and maintains the target price at $250.
According to TipRanks data, the analyst has a success rate of 41.5% and a total average return of -1.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biogen (BIIB.US)$'s main analysts recently are as follows:
The strategy to counterbalance the diminishing core franchises involves focusing on developing treatments for conditions that are underserved and challenging to address. The pipeline is perceived to carry a higher clinical risk relative to its major biotech counterparts, which, in turn, presents considerable potential value.
Biogen's collaboration with Eisai on the MAA for lecanemab in amyloid-positive early Alzheimer's disease has seen progress, as the request for reexamination by the EMA's CHMP has resulted in a favorable recommendation, albeit excluding APOE4 homozygotes. This development is perceived as making the application more acceptable to the European Commission, which is anticipated to decide on the approval within a 67-day timeframe.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
